Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SYNCOMF.NS
Strong BuyPremium GrowerSyncom Formulations (India) Limited · Healthcare · India · $208M · Avg Vol: $2M/d
95
StockRankGet insider-trade alerts
Q
81
V
38
M
82
P/E (TTM)
22.4x
ROE
18.4%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2.2B | 2.6B | 4.6B | 4.8B | 29.4% | 5.0B |
| EPS (INR) | 0.22 | 0.27 | 0.53 | 0.81 | 55.3% | 0.90 |
| Shares | 940.0M | 940.0M | 940.0M | 940.0M | 0.0% | 940.0M |
| Debt | 831.8M | 724.9M | 45.8M | 14.9M | -73.8% | 14.8M |
| Equity | 2.6B | 2.9B | 3.4B | 4.1B | 17.5% | — |
| Op CF | 105.3M | -59.6M | 234.4M | 580.8M | 76.7% | 582.8M |
| Inv CF | -449.5M | 830.2M | -182.0M | -506.2M | — | — |
| Fin CF | 350.0M | -145.6M | -679.0M | -30.2M | — | — |
Loading 1Y...
PRICE (1Y)+46.8%
SMA 50SMA 200
Close
$0.2018
RSI (14)
65.9
52W High
$0.2367
From 52W High
0.9%
SCORE BREAKDOWN
Quality
81
ROIC
26.6%95.2
ROE
18.4%86.7
GP/Assets
40.6%78.5
Op. Margin
19.7%82.4
FCF/Assets
8.7%83.3
Piotroski
549.3
Int. Cover
50.0x89.2
D/E Ratio
0.00x90.2
Current Ratio
3.18x57.6
Value
38
P/E (TTM)
22.4x54.9
EV/EBITDA
22.0x30.6
P/FCF
42.6x35.5
P/B
4.5x32.3
P/S
3.8x50.1
Div Yield
—N/A
Momentum
82
52W High %
85%77.1
RS 6M
59%93.0
SMA 50/200
1.10x75.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
58%76.5
FUNDAMENTALS
Market Cap
$208M
P/E (Forward)
—
Gross Margin
43.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SYNCOMF.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SYNCOMF.NS | Syncom Formulations (India) Limited(you) | $208M | 95 | Strong Buy |
| JAGSNPHARM.NS | Jagsonpal Pharmaceuticals Limited | $165M | 94 | Strong Buy |
| VENUSREM.NS | Venus Remedies Limited | $229M | 99 | Strong Buy |
| LINCOLN.NS | Lincoln Pharmaceuticals Limited | $135M | 99 | Strong Buy |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
| ANUHPHR.NS | Anuh Pharma Limited | $101M | 95 | Strong Buy |
| SAKAR.NS | Sakar Healthcare Limited | $268M | 79 | Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $413M | 87 | Strong Buy |
| AHCL.NS | Anlon Healthcare Limited | $88M | 90 | Strong Buy |
| SOLARA.NS | Solara Active Pharma Sciences Limited | $357M | 81 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%